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PENENTUAN JULAT RUJUKAN ASID VALPROIK DAN  
PERAMAL-PERAMAL KAWALAN SAWAN DI KALANGAN  
PESAKIT-PESAKIT EPILEPSI DI HOSPITAL KUALA LUMPUR 
 
ABSTRAK 
 
Asid valproik, ubat sawan berspektrum luas, telah dibuktikan berkesan dan mempunyai 
kesan sampingan yang rendah, tetapi kepentingan pemantauan kepekatannya dalam 
darah didapati kurang jelas. Kajian ini dijalankan untuk menentukan julat kepekatan 
berkaitan dengan keberkesanan dan kesan sampingan asid valproik dan faktor-faktor 
yang menentukan penyakit sawan dapat dikawal. Satu kajian pemerhatian secara 
retrospektif kohort telah dijalankan ke atas pesakit-pesakit yang menerima rawatan asid 
valproik di Klinik Neurologi, Hospital Kuala Lumpur. Kumpulan ‗respons baik‘ terdiri 
daripada pesakit-pesakit yang memperolehi 50% atau lebih penurunan kekerapan sawan. 
Kumpulan ‗respons lemah‘ terdiri daripada pesakit-pesakit yang tidak mencapai 
‗respons baik‘. Kekerapan sawan dikira dari rekod perubatan, catatan harian pesakit dan 
disahkan dari buku catatan yang dibekalkan semasa kajian. Pensampelan darah untuk 
menentukan kepekatan asid valproik dijalankan pada temujanji pertama dan pada bila-
bila masa sepanjang tempoh kajian. Buku catatan harian yang dibekalkan semasa kajian 
bertujuan untuk meningkatkan tahap kepatuhan terhadap ubat dan merekod kesan-kesan 
sampingan yang dialami. Seramai 242 pesakit menyertai kajian ini mulai Januari 2011 
dan diikuti selama setahun. Seramai 76 orang pesakit dari kumpulan ‗respons baik‘ dan 
bersetuju kepekatan darahnya dipantau digunakan untuk penentuan julat rujukan. 
Beberapa pendekatan diambil untuk menghasilkan julat rujukan, (i) menggunakan purata 
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atau median kepekatan, (ii) melalui julat kepekatan di mana peningkatan respons pesakit 
berlaku secara mendadak dengan meningkatnya kepekatan asid valproik, (iii) melalui 
julat komposit yang ditentukan secara mudah berdasarkan (i) dan (ii) untuk 
menghasilkan julat di mana kebanyakan pesakit mendapat ‗respons baik‘ dengan kesan 
sampingan yang minima. Jika lebih dari satu julat dihasilkan, julat-julat tersebut 
dianalisa secara statistik untuk mendapatkan julat yang paling sesuai. Julat rujukan yang 
ditunjukkan oleh kumpulan pesakit ini ialah 40 hingga 85mg/L. Kesan sampingan 
menggeletar dikaitkan dengan kepekatan asid valproik melebihi 80mg/L dan kehadiran 
kesan sampingan lain. Faktor penentu yang mengaitkan kesan rawatan yang baik untuk 
pesakit-pesakit sawan dengan asid valproik ialah umur semasa rawatan ubat sawan 
dimulakan [nisbah odd terselaras 0.96, 95% selang keyakinan (0.920, 0.995), P=0.027], 
rawatan dengan asid valproik sahaja [nisbah odd terselaras 4.74, 95% selang keyakinan 
(2.258, 9.947), P<0.001], keputusan imbasan MRI/CT yang normal [nisbah odd 
terselaras 5.83, 95% selang keyakinan (2.507, 13.552), P<0.001], tidak merokok [nisbah 
odd terselaras 3.23, 95% selang keyakinan (1.099, 9.473), P=0.033], dan ketiadaan 
tekanan [nisbah odd terselaras 19.98, 95% selang keyakinan (9.255, 42.764), P<0.001]. 
Kajian ini menunjukkan julat rujukan asid valproik untuk populasi ini dan faktor-faktor 
penting yang menentukan kesan rawatan yang baik untuk pesakit-pesakit sawan yang 
menggunakan asid valproik. 
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DETERMINATION OF VALPROIC ACID REFERENCE RANGE 
AND PREDICTORS FOR SEIZURE CONTROL AMONG PATIENTS WITH 
EPILEPSY AT HOSPITAL KUALA LUMPUR 
 
ABSTRACT 
 
Valproic acid, a broad spectrum anti-epileptic drug, had been proven efficacious and 
tolerable, but its serum drug concentration monitoring value remains obscure. This study 
was carried out to determine valproic acid concentration range associated with efficacy 
and tolerability, and the prognostic factors associated with seizure control. A 
retrospective cohort, observational study was conducted in patients who received 
valproic acid treatment in Neurology Clinic, Hospital Kuala Lumpur. ‗Good response‘ 
group were patients experiencing 50% or more seizure reductions. ‗Poor response‘ 
group were patients who did not achieve the definition of ‗good response‘. Seizure 
frequency was assessed from medical record, patients‘ own diary and verified by seizure 
diary supplied during this study. Blood sampling for determination of valproic acid 
concentration was done on the first encounter with the patient and/or at any time during 
the study period. Seizure diary was used as a tool to improve patient‘s adherence and 
record side effects occurrence. A total of 242 patients were recruited from January 2011 
and followed up for a year. Seventy-six patients with ‗good response‘ and consented to 
serum concentration monitoring were included for reference range determination. 
Several approaches were exercised to generate reference ranges, (i) mean or median 
concentration, (ii) range associated with a sudden increase in response with increasing 
valproic acid concentration, (iii) a composite concentration range based on (i) and (ii) 
xx 
 
determined arbitrarily to produce majority of patients with ‗good response‘ and minimal 
side effects. When more than one concentration ranges of potential exists, they were 
tabulated and statistically analyzed to find the most acceptable concentration range. The 
reference range provided by this population is 40 to 85mg/L. Tremor was associated 
with valproic acid serum concentration above 80mg/L and the presence of other side 
effects. Significant prognostic factors associated with good seizure response in patients 
with epilepsy on valproic acid were age at the initiation of AED [Adjusted OR 0.96, 
95% CI (0.920, 0.995), P=0.027], on valproic acid monotherapy [Adjusted OR 4.74, 
95% CI (2.258, 9.947), P<0.001], normal MRI/CT-scan [Adjusted OR 5.83, 95% CI 
(2.507, 13.552), P<0.001], non-smoking [Adjusted OR 3.23, 95% CI (1.099, 9.473) 
P=0.033] and absence of stress [Adjusted OR 19.98, 95% CI (9.255, 42.764), P<0.001]. 
This study described valproic acid reference range for this population and highlighted 
the important prognostic factors that were associated with favorable seizure response in 
patients with epilepsy on valproic acid. 
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CHAPTER ONE 
 
INTRODUCTION 
 
 
1.1 Disease Burden 
 
Epilepsy is associated with high morbidity and mortality which ultimately affect the 
country‘s economic burden and patients‘ socioeconomic status. Epilepsy-related 
negative outcomes incur high direct healthcare cost and indirect cost. Indirect cost 
relates to qualitative and quantitative loss of productivity, income and social well-being. 
 
1.1.1 Impact on Morbidity and Quality of Life 
 
Although epilepsy takes place in the brain, it profoundly influences the morale, 
wellbeing, self-image and lifestyle of patients (Betts 1992). It has negative impact on 
patient‘s quality of life, which was worsen by the adverse effects of antiepileptic 
treatments (Rogvi-Hansen & Gram 1995, Yue et al. 2011). It is also associated with 
psychiatric morbidity (Dias et al. 2010). 
 
A large scale Quality Of Life (QOL) study in more than 5,000 patients with epilepsy in 
15 European countries by Baker et al. (1997) has shown negative impact of epilepsy on 
social and psychological well-being. Significant reductions were found in physical, 
social and emotional functioning. A similar study in the United Kingdom by Moran et 
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al. (2004) confirmed the negative impact of epilepsy. It causes work and school 
difficulties and driving prohibitions as well as affecting psychological and social life. 
Loss of seizure control leads to missed school or a permanent drop from school or work 
as a result of cognitive impairment in 38% of the patients and perceived stigma in 31% 
(Hovinga et al. 2008).  
 
Depression is common in patients with epilepsy (Roth et al. 1994, Hecimovic et al. 2003, 
Kanner 2007, Ekinci et al. 2009, Dias et al. 2010). It occurs more often in patients whose 
seizure is not in remittance (Jacoby et al. 1996) and those who lead stressful life events 
(Roth et al. 1994). In addition, young patients with epilepsy reported increased anxiety 
and more emotional and behavioral difficulties (Ekinci et al 2009, Eddy et al. 2010). 
Psychiatric comorbidities, lack of seizure control, motor impairment and cognitive 
impairment also contribute to various physical injuries (Wirrell 2006). 
 
Physical injuries lead to frequent physician visits, hospitalizations and reduced 
productivity from missing schools and works (Begley et al. 1999, Wirrell 2006, Davis et 
al. 2008, Hovinga et al. 2008). In patients with epilepsy, there is an increased likelihood 
of hospitalizations and motor-vehicle accidents due to seizure compared to other 
population (Hovinga et al. 2008). There is a two-fold increase in risk of fractures, either 
as a direct effect of seizure-induced injury or due to drug-induced reduction in mineral 
bone density (Wirrell 2006).  
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In a study by Persson et al. (2002), 11% of 177 patients with epilepsy sustained 23 
fractures which prompted them to seek medical attention at the emergency department. 
This study compared the incidence of extremity fractures in adult patients with epilepsy 
with the incidence of fractures in the general population in the same geographic area. 
They found that the relative risk of fractures was higher during the first and second year 
compared with more than 5 years after diagnosis (RR, 3.71; 95% CI, 1.20–11.48). Male 
aged 45 years or older and those with generalized seizures were particularly at risk. This 
finding was supported by Kwon et al. (2010). The 1-year incidence of one or more 
injuries was significant among persons with epilepsy (20.6%) compared to those without 
epilepsy (16.1%, p < 0.001). Of the 16 types of injuries studied, 11 were higher in 
persons with epilepsy compared to those without epilepsy, which included head and 
skull fractures (OR = 2.6, 95% CI 1.6–4.2), neck/thoracic/trunk fracture (OR = 2.2, 95% 
CI 1.6–3.2), upper limb fracture (OR = 1.3, 95% CI 1.0–1.6) and lower limb fracture 
(OR = 1.8, 95% CI 1.4–2.3). Other injuries reported were upper limb dislocation (OR = 
1.4, 95% CI 1.0–2.1), neck/thoracic/trunk crushing injury (OR = 1.1, 95% CI 1.0–1.3), 
upper limb crushing injury (OR = 1.3, 95% CI 1.2–1.5), lower limb crushing injury (OR 
= 1.3, 95% CI 1.1–1.5), intracranial injury (OR = 1.7, 95% CI 1.3–2.3), other head 
injury (OR = 2.2, 95% CI 1.9–2.5), and multiple injuries (OR = 1.6, 95% CI 1.1–2.5).  
 
Long-term antiepileptic drugs have been significantly associated with the acceleration of 
atherosclerosis in patients with epilepsy (Tan et al. 2009). Chronic exposure to AEDs 
may alter the oxidative/antioxidative balance that results in oxidative stress which further 
damages endothelial cells (via increase in carotid intima media thickness) and 
contributes to the atherosclerotic process (Hamed et al. 2007). To my knowledge, there 
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is no data on increase acute coronary syndrome among patients with epilepsy. Currently 
available research showed increased in atherosclerosis biomarkers in patients with AEDs. 
Hamed et al. (2007) provided the first report on the high vulnerability of developing 
atherosclerosis among patients with epilepsy. Approximately 50% of patients with 
epilepsy developed thickened carotid artery. Carbamazepine and valproic acid showed 
significant alterations in certain atherosclerosis biomarkers.  
 
1.1.2 Impact on Mortality 
 
Patients with epilepsy have a higher risk of incurring accidental injury than those 
without seizure, which may also lead to death. Seizures may lead to abrupt falls 
consequently leading to head, bone or soft tissue injury. These patients may fall into 
water, causing submersion injury, or onto hot surface, causing burns. Submersion injury 
may cause death and is of major concern. In children with epilepsy, the risk of 
submersion are 7.5 to 13.9 fold higher than in general population (Wirrell 2006). In rural 
Bangladesh, mortality in adult patients with epilepsy due to accidental injury accounts to 
3.8% of all injury deaths. Causes of mortality were drowning and burns. The proportions 
of death due to drowning in patients with epilepsy was significantly higher than standard 
population (83% vs 7%) (Mateen et al. 2012).  
 
‗Sudden unexpected/unexplained death in epilepsy‘ (SUDEP) is a sudden unexpected 
death in epilepsy in which autopsy fails to reveal an anatomic or toxicological cause of 
death (Timmings 1993, Coyle et al. 1994, Nashef 1997). Recently, Nashef et al. (2012) 
unified the definition of SUDEP as ―Sudden, unexpected, witnessed or unwitnessed, 
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non-traumatic and non-drowning death, occurring in benign circumstances, in an 
individual with epilepsy, with or without evidence for a seizure and excluding 
documented status epilepticus (seizure duration >30 min or seizures without recovery in 
between), in which post-mortem examination does not reveal a cause of death‖. ‗Benign 
circumstances‘ which have been included in the definition refer to instantaneous death in 
patients with epilepsy without apparent reason. It is the most important epilepsy-related 
cause of death. This unified definition resolves current ambiguities, helps identify 
SUDEP cases and prevents misdiagnosis that would lead to SUDEP cases not have been 
investigated. 
 
SUDEP incidence is common in young patients with refractory epilepsy aged less than 
50 years. The overall incidence rate of SUDEP was 2.2 per 1,000 person-years (Derby et 
al. 1996) in United Kingdom and 0.54 to 1.35 SUDEP per 1,000 person-years in Canada 
(Tennis et al. 1995). Recently, Tomson et al. (2005) reviewed 14 studies to find the 
incidence of SUDEP in different epilepsy population. The incidence was 0.35 cases per 
1,000 person-years in community-based population, 1–2 per 1,000 person-years in 
chronic epilepsy, and 3–9 per 1,000 person-years in refractory seizures.  
 
Studies have been carried out to find the risk factors for SUDEP. Tennis et al. (1995) 
associated male sex, polytherapy and prescriptions of psychotropic substances with 
SUDEP. Nilsson et al. (2001) put forth factors indicating severe epilepsy as risk factors 
including high concentration of carbamazepine levels although Opeskin et al. (1999) had 
not supported it. A recent study by Thomas et al. (2005) had not found association of 
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SUDEP with any particular antiepileptic drugs. They found the risk factors to SUDEP 
were seizure frequency, onset at early age and long duration of disorders. Hesdorffer et 
al. (2012) analysed four case-control studies of SUDEP from USA, Sweden, Scotland 
and England. They found that the risk factors for SUDEP were increased frequency of 
generalized tonic–clonic seizures, use of polytherapy, duration of epilepsy, young age at 
onset, gender, symptomatic etiology, and lamotrigine therapy. Due to its unknown 
pathological mechanism, methods to prevent SUDEP are directed at its risk factors 
(Elson et al. 2009). 
 
Suicides have been attributed to epilepsy. Kanner (2010) found that about 12% death in 
patients with epilepsy was caused by suicide. The risk of committing suicide is 2-fold 
higher in patients with epilepsy alone compared to general population. This risk 
increases with the presence of concomitant disease like mood disorder, anxiety and 
psychotic disorder by 32-fold, 12.5-fold and 11.5-fold, respectively.  
 
In 2008, the U.S. Food and Drug Administration (FDA) issued an alert to health care 
professionals about an increased risk of suicide ideation and suicide behaviour in 
patients treated with antiepileptic drugs. Such a conclusion came from a meta-analysis of 
11 antiepileptic drugs, namely carbamazepine, felbamate, gabapentin, lamotrigine, 
levetiracetam, oxcarbazepine, pregabalin, tiagabine, topiramate, valproic acid, and 
zonisamide for epilepsy, psychiatric indications and ‗‗other conditions‘‘. In the main 
analysis, almost 28,000 people taking antiepileptic drugs and 16,000 people taking 
placebo were considered. There were four completed suicides altogether, all in people 
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taking antiepileptic drugs and none in those taking placebo. The FDA concluded that 
patients receiving antiepileptic drugs were twice more likely to experience suicidal 
behaviour or ideation compared with placebo. In addition, they observed that the relative 
risk was higher in patients treated for epilepsy compared to psychiatric illnesses or other 
conditions.  
 
1.1.3 Impact on economic burden and socioeconomic status 
 
Epilepsy increases economic burden to patients and society through direct and indirect 
cost. Direct cost is incurred in the management of seizure-related events, complications 
and medical expenses. Indirect cost is incurred due to loss of employment leading to the 
need for welfare medical fund and low socioeconomic living. 
 
Begley et al. (1999) compared the cost of epilepsy in United States, United Kingdom 
and Switzerland. In the United States, total lifetime cost of all patients with epilepsy was 
estimated at $3 billion, in which 62% was the indirect cost. Total hospital cost was 
estimated at more than $500 million and physician services cost at almost $80 million. 
The total annual cost for epilepsy in United Kingdom was estimated at $2.9 billion, in 
which nearly 70% was due to indirect cost. With the average medical cost per patient at 
$917, a projected total cost of $27 million was estimated for management of seizure 
disorders in the first year. The total direct cost in Switzerland was $211.1 million, with 
46% incurred by patients with intractable seizures. Seventy-two percent of the calculated 
indirect cost ($113.7 million) was due to unemployment.  
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Hong et al. (2009) performed cross-sectional cost-of-illness study on 289 patients with 
epilepsy in China. The calculated annual direct cost was $483 and the indirect cost was 
$289, making a total of $773 per patient. A similar study in India by Thomas et al. 
(2001) for 285 patients found that the annual direct cost per patient was $93 and the 
indirect cost was $251 per patient, lower than those reported in United Kingdom, United 
States and Germany.  
 
Jennum et al. (2011) calculated the direct and indirect costs associated with epilepsy in 
Denmark. They found that the net annual healthcare and indirect cost were 15 times 
higher for patients with epilepsy compared to person without epilepsy. In Nigeria, 
women with epilepsy have lower socioeconomic status when compared with women 
with other medical conditions. Women with epilepsy in Nigeria are not employed and 
had lower mean income. They are socially stigmatized, had fewer years of education, 
lower marriage rates, physically abused, sexually abuse and had poorer living 
environment (Komolafe et al. 2012). To my knowledge, there is no data regarding 
economic burden and socioeconomic status for patients with epilepsy in Malaysia. 
 
1.2  Pharmacotherapy of epilepsy 
 
Numerous guidelines on management of epilepsy in children and adults have been 
produced by American Academy of Neurology (AAN) and American Epilepsy Society 
(AES), Scottish Intercollegiate Guidelines Network (SIGN), National Institute for 
Health and Clinical Excellence (NICE), International League Against Epilepsy (ILAE) 
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and Consensus Guidelines on the Management of Epilepsy by Epilepsy Council, 
Malaysia Society of Neurosciences. These guidelines have addressed the proper 
management and pharmacotherapy in adult and children with epilepsy. 
 
Performing the right diagnosis is the first important step in the epilepsy treatment model 
(Schmidt 2002). Initiating the right antiepileptic the first time is crucial (Kwan & Brodie 
2001). Late treatment leads to suboptimal seizure control and adversely affects the 
prognosis (Choi et al. 2011). Furthermore, inappropriate prescribing of anti-epileptics 
incurs significant cost to the healthcare system (Juarez-Garcia et al. 2006).  
 
Prophylactic treatment has been advocated in patients with symptomatic etiology, while 
immediate treatment (within 1 week of injury) may reduce the risk of post-traumatic 
seizure disorder (PTSD). Patients should not be treated if the diagnosis is not confirmed. 
Patients with a certain diagnosis of unprovoked GTCS should be treated after the first 
seizure if there were previous absence or myoclonic seizures and if recurrence is 
expected (e.g. in the case of underlying structural brain abnormality). Otherwise, 
treatment may be initiated after the second seizure. Initiation of treatment for simple and 
complex partial seizures depends on seizure frequency, severity and patient‘s preference 
(SIGN 2003, Epilepsy Council MSoN 2010, NICE 2012). Seizures due to alcohol 
withdrawal symptoms, seizure induced by metabolic or drug-related cause, and seizure 
due to sleep deprivation should not be treated with AEDs (Schmidt 2002, SIGN 2003, 
Epilepsy Council MSoN 2010, NICE 2012). 
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Patients with recurrent seizures and confirmed diagnosed as having epilepsy should be 
treated with monotherapy AED, commencing with a low dose and titrated to achieve 
optimal seizure response and minimal side effects. If the first AED fails to control 
seizure at maximum tolerated dose, a second alternative AED may be introduced slowly 
without tapering the first. If the patient has a good response to the second AED, the first 
AED may be considered to be withdrawn (Schmidt 2002, SIGN 2003, Epilepsy Council 
MSoN 2010, NICE 2012).  
 
Recent studies have shown the superiority of monotherapy over polytherapy (Brodie et 
al. 2012), supporting the findings from earlier studies (Covanis et al. 1982, Chadwick 
1987, Bourgeois et al. 1987), even though earlier studies have shown otherwise (Deckers 
et al. 2001). From a total of 1,098 newly diagnosed adolescent and adult patients with 
epilepsy, 749 (68%) attained at least 1 year seizure freedom, in which 678 (62%) 
patients were on monotherapy. There was a higher probability of seizure freedom in 
patients receiving 1 compared to more AEDs (p<0.001)(Brodie et al. 2012).  
 
Polytherapy may be initiated in patients with recurrent seizures when treatment with 
monotherapy regime fails to achieve desired clinical outcome (SIGN 2003, Epilepsy 
Council MSoN 2010, NICE 2012). Some patients did not achieve seizure freedom 
(Brodie et al. 2012) while some of them attained fluctuations between seizure freedom 
and seizure relapse (Sillanpӓӓ & Schmidt 2006, Brodie et al. 2012). Seizure control 
remains suboptimal for many patients with 30 to 40% of them continue to have seizure 
despite the use of multiple anti-epileptics (Choi et al. 2011). The use of polytherapy may 
result in poor tolerability of antiepileptic drugs owing to higher incidence of adverse 
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effects. Strategies to prevent overtreatment (unnecessary and excessive drug load) with 
antiepileptic drugs should be employed as outlined by Schmidt (2002) because the 
chance of seizure freedom declined with successive drug regimens, markedly from the 
first to the third and among patients with localization-related epilepsies (Brodie et al. 
2012). Lesser number of previously trialed AED resulted in a better clinical outcome in 
adult patients with drug-resistant epilepsy (Luciano & Shorvon, 2007). Even though 
many patients have been treated with two or more AEDs, there is little or no direct 
evidence that a particular combination is effective in different patients. Stephen et al. 
(2012) reported 64 successful AED combinations. Approximately seventeen percent 
patients remain seizure-free on 3 AEDs with 57 separate regimes in the year 2010 
compared to 12.7% in year 2000. Levetiracetam (10.2%) and topiramate (7.6%) were 
the new AEDs commonly represented in successful combinations. Indirect comparisons 
can be made from RCTs of new AEDs used as add-on therapy in patients with drug-
resistant focal seizures (Chadwick et al. 2009). Use of combination therapy should result 
in optimal seizure outcome (Stephen et al. 2012). The combination of lamotrigine and 
valproic acid have been shown to be pharmacodynamically synergistic (Pisani et al. 
1999, Stephen et al. 2012) and is a rational pharmacotherapy.  
 
Patients with newly diagnosed epilepsy who require treatment can be initiated on 
standard AEDs such as carbamazepine, phenytoin, valproic acid, phenobarbital, or on 
the new AEDs lamotrigine, gabapentin, oxcarbazepine, or topiramate. Choice of AED 
will depend on individual patient characteristics (French et al. 2004a, French et al. 
2004b).  
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1.2.1 Antiepileptic drugs  
 
Both new and old generation AEDs are generally equally effective in managing 
epilepsy. The newer drugs tend to have fewer side effects (French et al. 2004a, French et 
al. 2004b). The development of 7 new AEDs (i.e. Gabapentin, Lamotrigine, Topiramate, 
Tiagabine, Oxcarbazepine, Levetiracetam, and Zonisamide) for epilepsy in 1990s and 
2000s (Brodie 2003, French et al. 2004a, French et al. 2004b) has increased by the fact 
that the prior available old AEDs (i.e. Phenytoin, Carbamazepine, Phenobarbitone, 
Valproic Acid, Primidone, Ethosuximide) did not provide optimal care for patients with 
epilepsy. Their seizures were not adequately controlled, or they were experiencing side 
effects with these older AEDs. In addition to that, the older AEDs have complex 
pharmacokinetics. Four of the six AEDs available prior to 1990 (phenytoin, 
carbamazepine, phenobarbital, and primidone) are hepatic enzyme inducers. On the 
other hand, valproic acid is a potent hepatic inhibitor. Enzyme-inducing and enzyme-
inhibiting AEDs produce important interactions with many commonly used medications, 
such as warfarin, oral contraceptives and calcium channel antagonists. The newer agents 
are involved in many fewer drug interactions because they have little effect on the 
CYP450 enzyme system and other metabolic pathways. A few studies (Kwan & Brodie 
2000, Kwan & Brodie 2001) have indicated that patients with newly diagnosed epilepsy 
can be categorized into those who are treatment responsive or treatment resistant. These 
treatment responsive patients responded to low doses of essentially all the AEDs studied, 
both old and new. Because these patients will remain on the initial or second therapy for 
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several years, selecting the most tolerable AED with the least likelihood of negative 
impact on quality of life is important. The older AEDs have an advantage of broad 
familiarity, lower cost, known efficacy, wide availability via coverage by third party 
payers, and long-term experience. French et al. (2004a) reported that the new AEDs may 
be better tolerated than the standard, with equivalent efficacy. However, they did not 
compare the importance of other differences between old and new AEDs, such as 
simpler pharmacokinetics, absence of apparent disturbance of the hormonal milieu, 
better safety, and the need for less laboratory monitoring. It is difficult to make such 
comparisons in an evidence-based fashion. The new drugs are all substantially more 
expensive than the old. There is no literature that addresses the cost-benefit related to 
these issues. At present, there is insufficient evidence to determine effectiveness in 
newly diagnosed patients for tiagabine, zonisamide, or levetiracetam (French et al. 
2004a, French et al. 2004b). Some AED have been shown to induce exacerbation of 
seizures (Perucca et al. 1998), such as carbamazepine, phenytoin, vigabatrin, gabapentin 
and benzodiazepine. This should not be overlooked by the treating physicians. 
 
The choice of AEDs for certain types of seizures and patients have been outlined in 
numerous guidelines (NICE 2012, SIGN 2003, SIGN 2005, French et al. 2004a, French 
et al. 2004b, Epilepsy Council MSoN 2010), studies (Chiron et al. 1997, Vigevano et al. 
1997, Motte et al. 1997, Nielsen et al. 1997, Beran et al. 1998, Guerrini et al. 1998, 
Perucca et al. 1998, Frank et al. 1999, Privitera et al. 2003, Poza 2007) and reviews 
(Brodie & French 2000, O‘Brien & Gilmour-White 2005, Cramer et al. 2007, Poza 2007, 
Stefan 2011). 
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The AED of choice for generalized seizure is valproic acid and it has been proven 
superior to topiramate in the Standard And New Antiepileptic Drugs (SANAD) study 
(Marson et al. 2006). If absence or myoclonic seizures or JME is suspected, lamotrigine, 
carbamazepine, oxcarbazepine, gabapentin, phenytoin, pregabalin, tiagabine or 
vigabatrin cannot be initiated because they may exacerbate myoclonic seizures (SIGN 
2005, NICE 2012). Nielsen et al. (1997) and  Perucca et al. (1998) have also reported 
that oxcarbazepine, vigabatrin and tiagabine aggravate absence seizures and myoclonic 
jerks.  Absence seizure should be treated with ethosuximide, valproic acid or lamotrigine 
(SIGN 2003, NICE 2012). Patient with myoclonic seizure should be treated with 
valproic acid as the first line AED. Levetiracetam and topiramate may be considered as 
alternative but the latter has less favorable side effect profiles compared to the others 
(NICE 2012). For infantile spasms, the first line treatment is steroid or vigabatrin for 
West‘s syndrome secondary to tuberous sclerosis (SIGN 2005, NICE 2012). Valproic 
acid has also been suggested as the first line treatment for Dravet syndrome, Lennox-
Gastaut syndrome, IGE, JME, childhood absence epilepsy, juvenile absence epilepsy 
and generalized tonic-clonic (GTC) only (NICE 2012). Felbamate is limited to the 
management of Lennox-Gastaut syndrome and partial seizures refractory to other AED 
due to its severe bone marrow and hepatotoxicity effects (French et al. 1999). 
 
The first line treatment for partial seizure is carbamazepine (NICE 2012), but Marson et 
al. (2007) in the Standard And New Antiepileptic Drugs (SANAD) study has proven that 
Lamotrigine is superior in tolerability and efficacy compared to valproic acid. On the 
other hand, Tudur Smith et al. (2007) showed otherwise. Lamotrigine was superior 
compared to carbamazepine, oxcarbazepine, valproic acid, topiramate, gabapentin, 
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phenytoin and phenobarbitone in terms of tolerability, but was found inferior compared 
to carbamazepine in terms of time to achieving a 12-months remission for partial 
seizures. However, valproic acid, oxcarbazepine and levetiracetam had been suggested 
as alternative AEDs to carbamazepine in treatment of partial seizures (NICE 2012).  
 
1.2.2 Pharmacotherapy in special populations 
 
The management of women with epilepsy created special problems which are related to 
their hormonal changes, which start at the menarche and continue until after the 
menopause. Many women report that their seizure episodes occur in relation to their 
menstrual periods. The precise reason for catamenial epilepsy is unknown, but may be 
related to the fact that estrogen is softly epileptogenic, whereas progesterone is weakly 
antiepileptogenic (O‘Brien & Gilmour-White 2005, Cramer et al. 2007). The rapid 
reduction in serum progesterone concentrations just before a period may make women 
more susceptible to epilepsy at that time. Changes in fluid balance may also play a part, 
but giving diuretics starting a week before a period is due is not effective. It may then be 
reasonable to give an additional AED starting a few days before a period is due. For 
practical purposes this needs to be a quick acting drug (e.g. clobazam, clonazepam or 
acetazolamide) that can be given at full dose in addition to the ongoing drug. Menopause 
tends to occur earlier in women with epilepsy. There is often an unpredictable increase 
or decrease in seizure frequency at different phase of menstrual cycle and pre-
menopause and post-menopausal period (Harden et al. 1999). Valproic acid and 
polytherapy should be avoided throughout pregnancy to decrease the risk of congenital 
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malformations and cognitive outcomes (Harden et al. 2009). Phenytoin and 
phenobarbitone should be avoided during pregnancy to decrease the risk of cognitive 
outcomes (Harden et al. 2009). AED use is an independent predictor of increased risk of 
fractures from the effect of AEDs on vitamin D (Persson et al. 2002). AEDs, age and 
postmenopausal status added to risk of osteoporosis. Therefore, women with epilepsy 
should have a bone health screen and be advised accordingly (Drezner 2004). 
 
The incidence of epilepsy in elderly has increased steadily over the last few decades. 
Epilepsy is the third most common neurologic disorder in elderly, after cerebrovascular 
disorder and dementia. The most common etiology of seizure was stroke. The most 
common types of seizure were simple partial and complex partial seizure with or without 
secondary generalization (Stefan 2011). The choice of AED for elderly fundamentally 
depends on its pharmacokinetic profile and possible side effects (Poza 2007, Brodie et al. 
2009, Stefan 2011). AED (e.g. valproic acid) which causes metabolic side effects may 
lead to acquiring diabetes, cardiovascular mortality and osteoarticular problems in 
elderly patients (where the risk is already high) is not recommended. AED with 
cognitive side effects (e.g. Phenobarbitone, Topiramate, Tiagabine) and osteoporosis 
(e.g. Phenobarbitone) are not suitable for elderly patients. AED which enable rapid dose 
titration and allow intravenous administration, such as phenytoin, may have some value 
but limited due to its complex pharmacokinetic profile. Carbamazepine has minimal 
cognitive effect but it has hepatic capacity causing high interaction with other drugs. 
Lamotrigine does not cause cognitive side effects but its hepatic metabolism may be of 
concern (Anderson et al. 2002). Newer AED with favorable linear kinetics and lower 
potential for side effects (e.g. lamotrigine, levetiracetam, pregabalin, oxcarbazepine) is 
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highly suitable for this population (Poza 2007). On the other hand, Stefan (2011) 
recommended low dose valproic acid (30 to 40% less than usual adult dose) as the most 
effective AED for elderly compared to phenytoin. Newer AED of choice are lamotrigine 
and gabapentin (Brodie et al. 2009, Stefan 2011). Based on US rating between 2000 and 
2004, the first line AED used for elderly patient were lamotrigine, levetiracetam, 
gabapentin, carbamazepine and oxcarbazepine, followed by topiramate and valproic acid. 
In German, Austria and Swiss, the rating in 2007 showed the first line AED used for 
elderly were levetiracetam, lamotrigine and gabapentin, followed by topiramate and 
valproic acid. Oxcarbazepine and carbamazepine were not recommended due to 
hyponatremia, cardiac disorders and drug interactions (Stefan 2011).  
 
The prognosis of seizure freedom in patients with newly diagnosed epilepsy varies 
widely from 22% to 80% (Elwes et al. 1984, Mattson 1994). Early control may affect 
long term prognosis. The longer the seizures continue after the start of treatment, the less 
likely it is controllable (Elwes et al. 1984, Luciano & Shorvon 2007, Choi et al. 2011). 
Del Felice et al. (2010) reported that the cumulative probability of 2-year remission in 
newly diagnosed patients with epilepsy was 56.3% at 2 years after start of treatment, and 
62.6, 69.4 and 79.5% at 3,5 and 10 years, illustrating a slow progression in overall 
achievement as duration of disease prolonged. Luciano & Shorvon (2007) found that 
shorter duration of epilepsy was associated with a better clinical outcome in adult 
patients with drug-resistant epilepsy. 
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Seizures which continue beyond 2 to 3 years are considered as chronic epilepsy. 
Appropriate review of clinical aspects of the illness and pharmacotherapy must be 
worked out (Epilepsy Council MSoN 2010). Adequate drug trials should be advocated 
(SIGN 2003, Epilepsy Council MSoN 2010, NICE 2012). Del Felice et al. (2010) 
reported that the cumulative probability of 2-year remission in newly diagnosed patients 
with epilepsy was 56.3% at 2 years after start of treatment, and increased at a slower rate 
up to 10 years to 79.5% with adequate pharmacotherapy.  
 
When seizure freedom has been sustained for a period of at least 2 years, drug 
withdrawal may be considered (Epilepsy Council MSoN 2010). When AED is being 
discontinued, it should be tapered down slowly (at least 2 to 3 months) and done so with 
one drug at a time (SIGN 2003, NICE 2012).  
 
1.2.3 Antiepileptic drugs utilization pattern 
 
The pattern of AED use differs between countries (Malerba et al. 2010, Ayadurai et al. 
2011, Landmark et al. 2011) and between neurologists (Smeets et al. 1999). In Norway, 
Landmark et al. (2011) evaluated more than 4 million prescriptions of antiepileptic drugs 
from 2004 to 2009. They found that the four most commonly used antiepileptics drugs 
were carbamazepine, valproic acid, lamotrigine and levetiracetam which contributed to 
68% of total antiepileptics used. The most common combination therapies were 
lamotrigine and valproic acid (42%), and carbamazepine and levetiracetam (19%). 
Newer antiepileptics were more commonly used in women compared to men. In children, 
most commonly used antiepileptics were valproic acid and lamotrigine.  
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Malerba et al. (2010) did a similar evaluation on the pattern of antiepileptic drug 
prescriptions for 933 adult and 191 children with refractory epilepsy in 11 tertiary 
centers in Italy. Their findings were similar to the other author. Most commonly used 
antiepileptics were carbamazepine, valproate, lamotrigine and levetiracetam. The used 
of antiepileptic drugs in adult were levetiracetam (35%), carbamazepine (34%) and 
lamotrigine (30%). In children, valproic acid (46%), carbamazepine (27%), topiramate 
(21%) and phenobarbitone (20%) were used. For treatment of partial epilepsy, 
carbamazepine (37%), levetiracetam (33%) and lamotrigine (26%) were used. In 
generalized epilepsy, valproic acid (62%), lamotrigine (33%) and levetiracetam (28%) 
were used. Polytherapy was used in 79% adult and 73% children. Second generation 
antiepileptic drugs were used in 81% adult and 54% children. 
 
In Malaysia, antiepileptic drug utilization has been described by Ayadurai et al. (2011) 
and Ab Rahman et al. (2005).  Ayadurai et al. (2011) described AED utilization in 618 
patients aged between 12 and 85 years old, seen in Penang Hospital. Most commonly 
used antiepileptic drugs were carbamazepine (28%), valproic acid (39%), phenytoin 
(24%) and lamotrigine (9%). More than 55% patients were on monotherapy and 41.1% 
on polytherapy. Ab Rahman et al. (2005) described AED utilization in 180 children and 
young adolescent aged between 6 months to 19 years. 64% of them were on 
monotherapy in which valproic acid were commonly prescribed (36%), followed by 
carbamazepine (21%), and other less frequently prescribed AED such as clonazepam 
and phenobarbitone. Majority of 22% patients on dual therapy were on combination of 
valproic acid with another AED such as clonazepam and carbamazepine. 
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1.3 The role of valproic acid in the treatment of epilepsy 
 
Despite its use for almost 50 years, valproic acid remains an important drug in the 
treatment of epilepsy. It was previously known as n-dipropylacetic acid (DPA). Its 
anticonvulsant effect was first discovered in 1963 (Loiseau et al. 1975, Rogvi-Hansen & 
Gram 1995, Brodie 2010) and was used as early as 1967 in France (Löscher 2002, 
Perucca 2002, Brodie 2010), 1974 in Norway (Henriksen & Johannesen 1982), 1977 in 
UK and 1978 in USA. In Malaysia, valproic acid was registered and marketed in 1986 
(National Pharmaceutical Control Bureau, 2013). 
 
1.3.1 Pharmacology of valproic acid 
 
Valproic acid works via a combination of several neurochemical and neurophysiological 
mechanisms. It acts on diverse regional targets involved in the induction and 
propagation of seizures (Löscher 2002). This may explain its broad spectrum efficacy 
for several types of seizures because of its ability in counteracting diverse molecular and 
cellular pathophysiology that happens during seizure event.  
 
Valproic acid acts in balancing inhibition and excitation of neurons in the brain regions  
involved during pathogenesis of seizure by; (i) increasing turnover of γ-aminobutyric 
acid (GABA) and potentiates its function to control seizure generation and propagation 
in some specific brain regions, (ii) controlling neuronal excitation mediated by N-
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methyl-D-aspartate (NMDA) subtype glutamate receptor, (iii) reducing the release of γ-
hydroxybutyrate (GHB) which has been suggested to be involve in the modulation of 
absences seizures, and (iv) blocking voltage-dependent sodium currents (Löscher 2002, 
Perucca 2002, Johannessen & Johannessen 2003).  Valproic acid is rapidly metabolized 
into pharmacologically active metabolite found in various body tissues namely (E)-Δ2-
VPA, Δ4-VPA and other metabolites such as 3-hydroxy-VPA, 4-hydroxy-VPA 5-
hydroxy-VPA 3-oxo-VPA, 3-keto-VPA, and others (Löscher  1981, Nau & Löscher 
1984, Baillie & Rettenmeier 1989, Semmes & Shen 1991). Both valproic acid and its 
metabolite limit the firing of neurons which trigger seizures in a concentration-, voltage-, 
rate- and time-dependent fashion (Löscher 2002).   
 
Trans-2-en-valproate, i.e. (E)-Δ2-VPA, is the most potent valproic acid metabolite and 
has got higher potency than the parent drug (Baillie & Rettenmeier 1989, Löscher 2002). 
Since (E)-Δ2-VPA is cleared from the brain and plasma more slowly than the parent 
drug, it has been proposed that this metabolite accumulates with time in CNS and 
contributes to therapeutic effects of the parent drug. The relatively slow washout kinetics 
of (E)-Δ2-VPA as compared to the parent drug may account for the persistence of 
anticonvulsant activity following discontinuation of valproic acid administration (Baillie 
& Rettenmeier 1989). It is found in appreciable quantities in human brain (Baillie & 
Rettenmeier 1989) but considered not significant for the effects of valproic acid 
(Löscher 2002). Nevertheless, the presence of metabolite might explain the poor 
correlation between anticonvulsant activity with valproic acid serum concentration and 
the lengthy time course for anticonvulsant effect which differs from valproic acid 
pharmacokinetic, i.e. protection against seizure is not maximal until some times after the 
22 
 
attainment of steady-state concentration in serum or brain tissues, and persist long after 
the parent drug has been cleared from the systemic circulation (Nau & Löscher  1984, 
Pollack et al. 1986).  
 
Valproic acid exhibit ‗early‘ (i.e. occurring immediately after first administration of 
effective dose) and ‗late‘ (i.e. developing during long-term administration) 
anticonvulsant effects. Löscher & Hönack (1995) reported marked increase in valproic 
acid anticonvulsant activity on the second day of treatment and days after, regardless of 
plasma concentration. Such increase in anticonvulsant activity was also observed by 
Davis et al. (1994) and Bourgeois et al. (1987). This means that a valproic acid dose or 
serum concentration being ineffective after a single-dose administration can become 
effective on long-term administration. This phenomenon may be explained by the time 
taken by valproic acid to reach its extracellular (e.g. ion channels) and intracellular (e.g. 
GABA synthesis) sites of action (Löscher 2002, Perucca 2002). Valproic acid uptake 
into the brain is facilitated by medium- and long-chain fatty acid selective anion 
exchanger via active transport system at the brain capillary epithelium. This explains 
how valproic acid enters the brain and reaches its extracellular sites so quickly 
(Lindberger et al. 2001, Löscher 2002, Perucca 2002) leading to the ‗early‘ 
anticonvulsant effect after a single dose. The ‗late‘ anticonvulsant effects most likely 
arise from its slow penetration into the neurons‘ intracellular sites of action (Löscher 
2002, Perucca 2002) and the effect of metabolites (Nau & Löscher  1984, Pollack et al., 
1986). 
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1.3.2 Efficacy of valproic acid 
 
Numerous clinical trials have suggested that valproic acid has antiepileptic activity in 
both children and adult with epilepsy (Covanis et al. 1986, Henriksen & Johannessen 
1982, Bourgeouis et al 1987, Marson et al. 2006, Marson et al. 2007, Levisohn & 
Holland 2007, Ollivier et al. 2009). Valproic acid has a broad spectrum of antiepileptic 
effects. It is effective against generalized and partial seizures, refractory syndromes like 
Lennox-Gastaut syndrome and West syndrome and mixed seizure types which have 
highly refractory symptoms (Covanis et al. 1986, Bourgeouis et al. 1987, Chadwick 
1987b, Löscher 2002, Perucca 2002, Nicolson et al. 2004, Ma et al. 2010). Furthermore, 
there is no contraindication to the use of valproic acid in any types of seizures or 
epilepsy (Perucca et al. 1998, Brodie & French 2000). Most adult requires 15 to 30 
mg/kg/day in 2 to 3 divided doses (Covanis et al. 1982, Bourgeouis et al. 1987, Eadie 
1998), to a maximum of 60 mg/kg/day. It is usually initiated with 400 to 600mg/day, to 
a maximum maintenance dose of 2500mg/day in divided doses (Epilepsy Council MSoN 
2010). 
 
Many studies support the use of valproic acid monotherapy for the treatment of epilepsy. 
Covanis et al. (1982) assessed 336 patients who received valproic acid. From 71% 
patients with valproic acid monotherapy, 83% achieved complete seizure freedom. The 
seizure freedom was achieved in 47% patients with partial epilepsy, more than 80% 
patients with generalized epilepsy and 72% patients with photosensitivity epilepsy. 
Similar findings were reported by Bourgeois et al. (1987), where 83% patients with 
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epilepsy achieved seizure freedom with valproic acid monotherapy. This included 56% 
patients who were switched from other antiepileptic drugs due to inadequate seizure 
control and intolerable side effects.  
 
An open clinical trial on 100 children who were on long term monotherapy and 
polytherapy valproic acid (Henriksen & Johannessen 1982) found that 71% had more 
than 50% seizure reduction, which included 33% who had total seizure freedom. 36% 
patients on monotherapy achieved good seizure control. 92% patients with absence 
seizure had better outcome compared to grand mal (67%), simple partial seizure (54%) 
and complex partial seizure (74%). Chadwick (1987b) had reviewed 4 open studies of 
valproic acid monotherapy which cover 527 patients for a minimum follow-up duration 
of 2 years. More than 80% of patients with primary generalized seizures achieved 
seizure freedom while patients with partial seizures achieved a lesser extend of 75%. 
 
Marson et al. (2006) provided a data on valproic acid through a multicenter study of 
early epilepsy and single seizures (MESS). The result significantly showed that patient 
treated with valproic acid immediately after diagnosis was associated with achieving 1-
year and 2-year remission sooner compared to delayed treatments. Valproic acid had 
been successful in treating photoconvulsive response in photosensitive patients at a 
higher rate in valproic acid naïve patients (78%) compared to 28% in previously valproic 
acid exposed patients (Rowan et al. 1979).   
 
